Repligen Corporation (RGEN) Presents at UBS Global Healthcare Conference 2025 Transcript

Core Insights - The company reported an 18% organic growth for the quarter, indicating strong performance across its diverse portfolio [2] - Orders increased by over 20%, reflecting robust demand and positive momentum [3] - Gross margin improved by more than 200 basis points year-over-year on a year-to-date basis, suggesting effective cost management and operational efficiency [3]